99 related articles for article (PubMed ID: 10487681)
1. Hormonal and volumetric long term control of a growth hormone-releasing hormone-producing carcinoid tumor.
Van den Bruel A; Fevery J; Van Dorpe J; Hofland L; Bouillon R
J Clin Endocrinol Metab; 1999 Sep; 84(9):3162-9. PubMed ID: 10487681
[No Abstract] [Full Text] [Related]
2. Acromegaly caused by a growth hormone-releasing hormone secreting carcinoid tumour of the lung: the effect of octreotide treatment.
de Jager CM; de Heide LJ; van den Berg G; Wolthuis A; van Schelven WD
Neth J Med; 2007; 65(7):263-6. PubMed ID: 17656813
[TBL] [Abstract][Full Text] [Related]
3. Ectopic growth hormone-releasing hormone secretion by a metastatic bronchial carcinoid tumor: a case with a non hypophysial intracranial tumor that shrank during long acting octreotide treatment.
Fainstein Day P; Frohman L; Garcia Rivello H; Reubi JC; Sevlever G; Glerean M; Fernandez Gianotti T; Pietrani M; Rabadan A; Racioppi S; Bidlingmaier M
Pituitary; 2007; 10(3):311-9. PubMed ID: 17373589
[TBL] [Abstract][Full Text] [Related]
4. Acromegaly caused by a growth hormone-releasing hormone-secreting carcinoid tumor: case report.
Altstadt TJ; Azzarelli B; Bevering C; Edmondson J; Nelson PB
Neurosurgery; 2002 Jun; 50(6):1356-9; discussion 1360. PubMed ID: 12015856
[TBL] [Abstract][Full Text] [Related]
5. Presence of somatostatin receptors negatively coupled to adenylate cyclase in ectopic growth hormone-releasing hormone- and alpha-subunit-secreting tumors from acromegalic patients responsive to octreotide.
Bertherat J; Turpin G; Rauch C; Li JY; Epelbaum J; Sassolas G; Schaison G
J Clin Endocrinol Metab; 1994 Nov; 79(5):1457-64. PubMed ID: 7962343
[TBL] [Abstract][Full Text] [Related]
6. Medical management of acromegaly due to ectopic production of growth hormone-releasing hormone by a carcinoid tumor.
Melmed S; Ziel FH; Braunstein GD; Downs T; Frohman LA
J Clin Endocrinol Metab; 1988 Aug; 67(2):395-9. PubMed ID: 2899089
[TBL] [Abstract][Full Text] [Related]
7. [Experience in treating acromegalic patients with long-acting octreotide].
Szücs N; Mészáros J; Czirják S; Mondok A; Varga I; Gláz E
Orv Hetil; 2002 May; 143(19 Suppl):1066-70. PubMed ID: 12063862
[TBL] [Abstract][Full Text] [Related]
8. Octreotide treatment of acromegaly during pregnancy.
Mikhail N
Mayo Clin Proc; 2002 Mar; 77(3):297-8. PubMed ID: 11888040
[No Abstract] [Full Text] [Related]
9. [Acromegaly associated with McCune-Albright syndrome].
Tóth M; Töke J; Kiss E; Bernád I; Miheller P; Szücs N; Rácz K
Orv Hetil; 2002 May; 143(19 Suppl):1070-3. PubMed ID: 12063863
[TBL] [Abstract][Full Text] [Related]
10. An unusual cause of acromegaly.
Lock KY; Lau IT; Yeung CK; Chan CP
Hong Kong Med J; 2014 Aug; 20(4):331-4. PubMed ID: 25104005
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
[TBL] [Abstract][Full Text] [Related]
12. Ectopic growth hormone-releasing hormone secretion by a neuroendocrine tumor causing acromegaly: long-term follow-up results.
Colak Ozbey N; Kapran Y; Bozbora A; Erbil Y; Tascioglu C; Asa SL
Endocr Pathol; 2009; 20(2):127-32. PubMed ID: 19301154
[TBL] [Abstract][Full Text] [Related]
13. Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies.
van Hoek M; Hofland LJ; de Rijke YB; van Nederveen FH; de Krijger RR; van Koetsveld PM; Lamberts SW; van der Lely AJ; de Herder WW; Feelders RA
J Clin Endocrinol Metab; 2009 Feb; 94(2):428-33. PubMed ID: 19017754
[TBL] [Abstract][Full Text] [Related]
14. [Acromegaly and bronchial carcinoid tumor. Apropos of a case].
Caron P; Guittard J; Trouillas J; Salvador M; Bayard F
Ann Endocrinol (Paris); 1992; 53(4):158-61. PubMed ID: 1305802
[TBL] [Abstract][Full Text] [Related]
15. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
Laczi F; Magony S; Julesz J
Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
[TBL] [Abstract][Full Text] [Related]
16. Carcinoid crisis and reversible right ventricular dysfunction after embolization in untreated carcinoid syndrome.
Majeed F; Porter TR; Tarantolo S; Duhachek-Stapelman A; Xie F; Elhendy A
Eur J Echocardiogr; 2007 Oct; 8(5):386-9. PubMed ID: 17011239
[TBL] [Abstract][Full Text] [Related]
17. Acromegaly caused by ectopic growth hormone: a rare manifestation of a bronchial carcinoid.
Biswal S; Srinivasan B; Dutta P; Ranjan P; Vaiphei K; Singh RS; Thingnam SS
Ann Thorac Surg; 2008 Jan; 85(1):330-2. PubMed ID: 18154841
[TBL] [Abstract][Full Text] [Related]
18. Bronchial carcinoid secreting insulin-like growth factor-1 with acromegalic features.
Phillips JD; Yeldandi A; Blum M; de Hoyos A
Ann Thorac Surg; 2009 Oct; 88(4):1350-2. PubMed ID: 19766843
[TBL] [Abstract][Full Text] [Related]
19. Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide.
Barakat S; Melmed S
Arch Intern Med; 1989 Jun; 149(6):1443-5. PubMed ID: 2730266
[TBL] [Abstract][Full Text] [Related]
20. Ectopic acromegaly.
Faglia G; Arosio M; Bazzoni N
Endocrinol Metab Clin North Am; 1992 Sep; 21(3):575-95. PubMed ID: 1521513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
